The erythropoietin receptor: Structure, activation and intracellular signal transduction

Trends in Endocrinology and Metabolism

Volumn 10, Issue 1, 1999, Pages 18-23

  Constantinescu, Stefan N ^a   Ghaffari, Saghi ^a   Lodish, Harvey F ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR;

ANIMAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DIMERIZATION; ERYTHROID CELL; ERYTHROPOIESIS; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 0033000191     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00101-5     Document Type: Review

References (48)

1. Wu H., Liu X., Jaenisch R., Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 83:1995;59-67.
2. de la Chapelle A., Traskelin A-L., Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. Sci. U. S. A. 90:1993;4495-4499.
3. D'Andrea A.D., Lodish H.F., Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell. 57:1989;277-285.
4. Livnah O.et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å Science. 273:1996;464-471.
5. De Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 255:1992;306-311.
6. Wrighton N.C.et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-464.
7. Hilton D.J., Watowich S.S., Murray P.J., Lodish H.F. Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Proc. Natl. Acad. Sci. U. S. A. 92:1995;190-194.
8. Miura O., Cleveland J.L., Ihle J.N. Inactivation of the erythropoietin receptor function by a point mutation in a region having homology with other cytokine receptors. Mol. Cell. Biol. 13:1993;1788-1795.
9. Witthuhn B.A.et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:1993;227-236.
10. Wu H., Klingmüller U., Besmer P., Lodish H.F. Interaction of the erythropoietin and stem-cell-factor receptors. Nature. 377:1995;242-246.
11. Kapur R.et al. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood. 91:1998;879-889.
12. Levin I.et al. Identification of a cytoplasmic motif in the erythropoietin receptor required for receptor internalization. FEBS Lett. 427:1998;164-170.
13. Subtil A., Delepierre M., Dautry-Varsat A. An alpha-helical signal in the cytosolic domain of the interleukin 2 receptor beta chain mediates sorting towards degradation after endocytosis. J. Cell. Biol. 136:1997;583-595.
14. Watowich S.S., Hilton D.J., Lodish H.F. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol. Cell. Biol. 14:1994;3535-3549.
15. Elliott S., Lorenzini T., Yanagihara D., Chang D., Elliott G. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J. Biol. Chem. 271:1996;24691-24697.
16. Yoshimura A., Longmore G., Lodish H.F. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 348:1990;647-649.
17. Longmore G.D., Lodish H.F. An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell. 67:1991;1089-1102.
18. Semenza G.L., Traystman M.D., Gearhart J.D., Antonarakis S.E. Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc. Natl. Acad. Sci. U. S. A. 86:1989;2301-2305.
19. Wolff L., Ruscetti S. Malignant transformation of erythroid cells in vivo by introduction of a nonreplicating retrovirus vector. Science. 228:1985;1549-1552.
20. Li J-P., D'Andrea A.D., Lodish H.F., Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 343:1990;762-764.
21. Chung S.W., Wolff L., Ruscetti S.K. Transmembrane domain of the envelope gene of a polycythemia-inducing retrovirus determines erythropoietin-independent growth. Proc. Natl. Acad. Sci. U. S. A. 86:1989;7957-7960.
22. Constantinescu S.N.et al. The anemic Friend virus gp55 envelope protein induces erythroid differentiation in fetal liver colony-forming units-erythroid. Blood. 91:1998;1163-1172.
23. Zon L.I., Moreau J.F., Koo J.W., Mathey-Prevot B., D'Andrea A.D. The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein. Mol. Cell. Biol. 12:1992;2949-2957.
24. Feng J.et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:1997;2497-2501.
25. Neubauer H.et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:1998;397-409.
26. Parganas E.et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:1998;385-395.
27. Yoshimura A., Lodish H.F. In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130. Mol. Cell. Biol. 12:1992;706-715.
28. Tilbrook P.A., Ingley E., Williams J.H., Hibbs M.L., Klinken S.P. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J. 16:1997;1610-1619.
29. Chin H.et al. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood. 91:1998;3734-3745.
30. Damen J.E.et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J. 14:1995;5557-5568.
31. Gobert S.et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J. 15:1996;2434-2441.
32. Klingmüller U., Bergelson S., Hsiao J.G., Lodish H.F. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8324-8328.
33. Teglund S.et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:1998;841-850.
34. Damen J.E., Cutler R.L., Jiao H., Yi T., Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J. Biol. Chem. 270:1995;23402-23408.
35. Klingmüller U.et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3016-3021.
36. Bergelson S., Klingmüller U., Socolovsky M., Hsiao J.G., Lodish H.F. Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors. J. Biol. Chem. 273:1998;2396-2401.
37. Jacobs-Helber S.M., Wickrema A., Birrer M.J., Sawyer S.T. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol. Cell. Biol. 18:1998;3699-3707.
38. Socolovsky M., Dusanter-Fourt I., Lodish H.F. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J. Biol. Chem. 272:1997;14009-14012.
39. -/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit. Blood. 92:1998;1491-1496.
40. Klingmüller K., Lorens U., Cantley L.C., Neel B.G., Lodish H.F. Specific recruitment of the hematopoietic protein tyrosine phosphatase SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 80:1995;729-738.
41. Sokol L., Prchal J.F., D'Andrea A., Rado T.A., Prchal J.T. Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. Exp. Hematol. 22:1994;447-453.
42. Yoshimura A.et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:1995;2816-2826.
43. Endo T.A.et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
44. Helgason C.D.et al. Targeted disruption of SHIP leads to hemopoitic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1998;1610-1620.
45. Stoffel R., Ledermann B., de Sauvage F.J., Skoda R.C. Evidence for a selective-permissive role of cytokine receptors in hematopoietic cell fate decisions. Blood. 90:1997;123 (abstr.).
46. Akashi K., Kondo M., von Freeden-Jeffry U., Murray R., Weissman I.L. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 89:1997;1033-1041.
47. -/- mice. Cell. 89:1997;1011-1019.
48. Wu H., Klingmüller U., Acurio A., Hsiao J.G., Lodish H.F. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1806-1810.